WITHDRAWAL REACTION AFTER DISCONTINUATION OF THERAPY WITH ANTIDEPRESSANTS, NEUROLEPTICS AND ANTICHOLINERGIC ANTIPARKINSONICS
Abstract
Background. A withdrawal reaction after reduction of dosage or discontinuation of antidepressants, neuroleptics and anticholinergic antiparkinsonics is often neglected in everyday clinical practice. Although neuroleptics and antidepressants do not cause dependence, withdrawal reaction is present in almost one third of patients, but is usually mild. In severe cases the withdrawal reaction might be misdiagnosed, which leads to inappropriate management.
Conclusions. Prevalence, clinical characteristics and some etiological hypotheses of withdrawal reaction for antidepressants, neuroleptics and anticholinergic antiparkinsonics are presented in a form to be useful in everyday clinical practice.
Downloads
References
Haddad PM, Quereshi M. Misdiagnosis of discontinuation symptoms. Acta Psychiatr Scand 2000; 102: 466–7.
Lader M. Benzodiazepine withdrawal states. In: Trimble MR ed. Benzodiazepine divided. New York: John Wiley, 1983: 17–31.
Lejoyeux M, Ades J, Mourat I et al. Antidepressant withdrawal syndrome. CNS Drugs 1996; 5: 278–92.
Dilsaver SC. Withdrawal phenomena associated with antidepressants and antipsychotics. Drug Saf 1994; 10: 103–14.
Haddad P. The SSRI discontinuation syndrome. J Psychopharmacol 1998; 12: 305–13.
Otani K, Sasa H, Kaneko S et al. Lack of withdrawal symptoms after discontinuation of mianserine. Lancet 1991; 337: 673–4.
Coupland NJ, Bell CJ, Potokar JP. Serotonine reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996; 16: 356–62.
Fava M, Mulroy R, Aupert J. Emergency of adverse events following discontinuation of treatment with extended release venlafaxine. Am J Psychiatry 1997; 154: 1760–2.
Dilsaver SC. The pathophysiology of substance abuse in affective disorders. An integrative model? J Clin Psychopharmacol 1987; 7: 1–10.
Dilsaver SC. Antimuscarinic agents as a substance of abuse. A review. J Clin Psychopharmacol 1988; 8: 14–22.
Walsh BT, Stiart JW, Whight L et al. Treatment of bulimia with monoaminooxidase inhibitors. Am J Psychiatry 1992; 139: 1629–30.
Taylor DP, Carter RB, Eison AS et al. Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry 1995; 56: Suppl 6: 3–11.
Lauber C. Nefazodone withdrawal syndrome. Can J Psychiatry 2000; 44: 285–6.
Benazzi F. Nefazodone withdrawal symptoms. Can J Psychiatry 1999; 43: 194–5.
Weiden P. Switching antipsychotic medication. J Clin Psychiatry Monograph 1997; 15: 34–7.
Hunt JI, Singh H, Simpson GM. Neuroleptic – induced supersensitivity psychosis: retrospective study of schizophrenic in patients. J Clin Psychiatry 1988; 49: 258–61.
Rosebush PI, Kennedy K, Dalton B et al. Protracted akathisia after risperidone withdrawal. Am J Psychiatry 1997; 154: 437–8.
Rowan AB, Malone RP. Tics with risperidone withdrawal. J Am Acad Child Adolesc Psychiatry 1997; 36: 162–3.
Lore C. Risperidone and withdrawal dyskinesia. J Am Acad Child Adolesc Psychiatry 2000; 39: 941–1.
Lane HY, Chang WH. Manic and psychotic symptoms following risperidone withdrawal in a schizophrenic patient. J Clin Psychiatry 1998; 59: 620–1.
Verghese C, DeLeon J, Nair C et al. Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics. Biol Psychiatry 1996; 39: 135–8.
Jeste DV, Gilbert PL, McAdams LA et al. Considering neuroleptic maintenance and taper on a continuum. Arch Gen Psychiatry 1995; 52: 209–12.
Luchins DJ, Freed WJ, Wyatt RJ. The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs. Am J Psychiatry 1982; 137: 1395–8.
Jellinek T, Gardos G, Cole JO. Adverse effects of antiparkinsonian drug withdrawal. Am J Psychiatry 1981; 138: 1567–71.
Kaminer Y, Munitz H, Wijsenbeek H. Trihexyphenidyl (Artane) abuse: euforiant and anxiolytic. Br J Psychiatry 1982; 140: 473–4.
Barnes TR, McPhillips MA. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia. Int Clin Psychopharmacol 1998; 13: Suppl 3: 49–57.
Petersen RC, Richelson E. Anticholinergic activity of imipramine and some analogues at muscarinic receptors of culture mouse neuroblastoma cells. Psychopharmacology 1992; 76: 26–8.
Jaffe JH, Sharpess SK. Pharmacological denervation supersensitivity in the central nervous system. Res Publ Assoc Res Nerv Ment Dis 1969; 46: 226–41.
Dilsaver SC, Feiberg M, Greden JF. Antidepressant withdrawal symptoms treated with anticholinergic agents. Am J Psychiatry 1983; 140: 249–51.
Dilsaver SC. Pharmacologic induction of cholinergic system up-regulation and supersensitivity in affective disorder research. J Clin Psychopharmacol 1986; 7: 56–72.
Dilsaver SC. Withdrawal phenomena associated with antidepressants and antipsychotic agents. Drug Saf 1994; 10: 103–14.
Wistedt B. A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients. Acta Psychiatr Scand 1981; 64: 65–84.
Creese I, Sibley DR. Receptor adaptation to centrally acting drugs. Ann Rev Pharmacol Toxicol 1981; 287: 451–4.
Sathananchan GL, Gershon S. Imipramine withdrawal: akathisia-like syndrome. Am J Psychiatry 1973; 130: 1286–7.
Schatzberg AF, Haddad P, Kaplan EM et al. Possible biological mechanisms of serotonine reuptake inhibitor discontinuation syndrome. J Clin Psychiatry 1997; 58: Suppl 7: 23–7.
Mallia G, White K, Gunderson S. Is there a serotoninergic withdrawal syndrome? Biol Psychiatry 1993; 33: 851–2.
Stoukides JA, Stoukides CA. Extrapyramidal symptoms upon discontinuation of fluoxetine. Am J Psychiatry 1991; 148: 1263–3.
Cohen RM, Campbell IC, Dauphin M et al. Changes in alfa and beta receptor density in rat brain as a result of the treatment with monoaminooxidase inhibitor antidepressants. Neuropharmacology 1992; 27: 293–8.
Charney DS, Menkes DB, Heninger GR. Receptor sensitivity and mechanism of action of antidepressant treatment: implication of the etiology and theory of depression. Arch Gen Psychiatry 1981; 38: 1160–80.
Otani K, Tanaka O, Kaneko S et al. Mechanisms of the development of trazodone withdrawal syndrome. Int Clin Psychopharmacol 1994; 9: 131–3.
Boisvert D, Chouinard G. Rebound cardiac arrhythmia after withdrawal from imipramine: a case report. Am J Psychiatry 1981; 138: 985–6.
Jeste DV, Lacro JP, Gilbert PL, Kline J, Kline N. Treatment of late life schizophrenia with neuroleptics. Schizophr Bull 1993; 19: 817–30.
Heaton R, Pausen J, McAdams LE et al. Neuropsychological deficits in schizophrenia: relationships to age, chronicity and dementia. Arch Gen Psychiatry 1994; 51: 469–76.
Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonine reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998; 44: 77–87.
Oehrberg S, Christiansen PE, Behnke K et al. Paroxetine in the treatment of panic disorder. Br J Psychiatry 1995; 167: 374–97.
Young A, Haddad P. Discontinuation symptoms and psychotropic drugs. Lancet 2000; 355: 1184–4.
Haddad P, Anderson I. Antidepressant are not addictive: clinicians have depended on them for years. J Psychopharmacol 1999; 13: 291–2.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
